Latest Search
Quote
| Back Zoom + Zoom - Top | ||||
|
<Research>Jefferies: WUXI BIO (02269.HK) Is Now at Inflection Point from PB Ratio Perspective
Recommend 25 Positive 54 Negative 29 |
||||
|
||||
|
Jefferies issued a research report saying that WUXI BIO (02269.HK) is now at an inflection point from a PB ratio perspective, and believing that its risk and reward profile is tipping towards more upside than downside. Therefore, Jefferies rated WUXI BIO at Buy, with a target price of $53. Investors are coming to a consensus on the geopolitical issues faced by WUXI BIO, Jefferies added. As the US Biosecure Act progresses, there will be more clarity to come, especially on how existing contracts will be handled. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
